Avastin gets to keep its breast cancer use in Europe

As Roche prepares for its Avastin hearing at the FDA, European regulators have decided to preserve the drug's breast cancer indication, but only in combination with the chemo drug paclitaxel. Pairing Avastin with another chemo drug, docetaxel, doesn't appear to help patients any more than docetaxel alone, EMA advisors said.

Roche was pleased with that decision, especially because it's facing the possibility that the FDA will nix the breast cancer indication altogether. "We are pleased that the European Commission is continuing to support Avastin in combination with paciltaxel," Roche CMO Hal Barron said in a statement. "This is important news for thousands of women living with incurable...breast cancer in the European Union."

The FDA's decision to pull Avastin's breast cancer indication has stirred up plenty of opposition, including some very vocal politicians in Washington. Despite support from a couple of key patient-advocacy groups and some cancer experts, the agency has had to tread carefully. That care will have to continue through Roche's appeal hearing in late June. Could the European approach be a way out for U.S. regulators?

- check out Roche's release
- see the InPharma story
- get more from MarketWatch

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.